JP2023508097A5 - - Google Patents

Info

Publication number
JP2023508097A5
JP2023508097A5 JP2022539058A JP2022539058A JP2023508097A5 JP 2023508097 A5 JP2023508097 A5 JP 2023508097A5 JP 2022539058 A JP2022539058 A JP 2022539058A JP 2022539058 A JP2022539058 A JP 2022539058A JP 2023508097 A5 JP2023508097 A5 JP 2023508097A5
Authority
JP
Japan
Application number
JP2022539058A
Other languages
Japanese (ja)
Other versions
JP7791087B2 (ja
JP2023508097A (ja
JPWO2021129653A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/138572 external-priority patent/WO2021129653A1/zh
Publication of JP2023508097A publication Critical patent/JP2023508097A/ja
Publication of JP2023508097A5 publication Critical patent/JP2023508097A5/ja
Publication of JPWO2021129653A5 publication Critical patent/JPWO2021129653A5/ja
Application granted granted Critical
Publication of JP7791087B2 publication Critical patent/JP7791087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022539058A 2019-12-23 2020-12-23 タンパク質分解剤化合物の製造方法及び使用 Active JP7791087B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201911342649 2019-12-23
CN201911342649.0 2019-12-23
CN202010200682 2020-03-20
CN202010200682.6 2020-03-20
CN202010496353 2020-06-03
CN202010496353.0 2020-06-03
CN202011486334 2020-12-16
CN202011486334.6 2020-12-16
PCT/CN2020/138572 WO2021129653A1 (zh) 2019-12-23 2020-12-23 一种蛋白降解剂化合物的制备方法和应用

Publications (4)

Publication Number Publication Date
JP2023508097A JP2023508097A (ja) 2023-02-28
JP2023508097A5 true JP2023508097A5 (https=) 2024-01-09
JPWO2021129653A5 JPWO2021129653A5 (https=) 2024-01-09
JP7791087B2 JP7791087B2 (ja) 2025-12-23

Family

ID=76573691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539058A Active JP7791087B2 (ja) 2019-12-23 2020-12-23 タンパク質分解剤化合物の製造方法及び使用

Country Status (19)

Country Link
US (2) US12441706B2 (https=)
EP (1) EP4083020A4 (https=)
JP (1) JP7791087B2 (https=)
KR (1) KR20220120629A (https=)
CN (2) CN113087704B (https=)
AU (1) AU2020414151A1 (https=)
BR (1) BR112022012385A2 (https=)
CA (1) CA3162523A1 (https=)
CL (1) CL2022001724A1 (https=)
CO (1) CO2022010305A2 (https=)
EC (1) ECSP22056811A (https=)
IL (1) IL294225B1 (https=)
JO (1) JOP20220159A1 (https=)
MX (1) MX2022007885A (https=)
PE (1) PE20230114A1 (https=)
PH (1) PH12022551571A1 (https=)
TW (1) TWI755992B (https=)
WO (1) WO2021129653A1 (https=)
ZA (1) ZA202208051B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
CA3165168A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
CN113801098B (zh) 2020-06-12 2023-05-30 上海济煜医药科技有限公司 酞嗪酮类化合物及其制备方法和医药用途
JP7834721B2 (ja) 2020-08-28 2026-03-24 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
IL301690A (en) * 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
AU2023300784A1 (en) * 2022-06-30 2025-01-02 Anhorn Medicines Co., Ltd. Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same
CN119948021A (zh) * 2022-07-15 2025-05-06 西藏海思科制药有限公司 一种含氮杂环衍生物及其组合物和药学上的应用
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
US12496301B2 (en) 2023-12-08 2025-12-16 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245804B1 (en) 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
AU2015247817C1 (en) 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
MX2017013563A (es) 2015-04-21 2018-07-06 Gtx Inc LIGANDOS DEGRADADORES SELECTIVOS DEL RECEPTOR ANDROGí‰NICO (SARD) Y SUS Mí‰TODOS DE USO.
HUE054149T2 (hu) 2015-06-04 2021-08-30 Arvinas Operations Inc Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2018071606A1 (en) * 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10842878B2 (en) 2016-11-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
CA3042301A1 (en) * 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
CN110194762B (zh) 2018-02-27 2021-09-10 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途
CN112390852B (zh) 2019-08-14 2022-10-18 上海济煜医药科技有限公司 作为蛋白降解剂的化合物及其制备方法和应用
CN112457367B (zh) 2019-09-06 2022-08-23 上海济煜医药科技有限公司 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN118085015A (zh) 2019-09-06 2024-05-28 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和用途
CN118930604A (zh) 2019-09-29 2024-11-12 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及包含其的药物组合物和应用
CN113582974B (zh) 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
CN113801098B (zh) 2020-06-12 2023-05-30 上海济煜医药科技有限公司 酞嗪酮类化合物及其制备方法和医药用途

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2023508097A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)